Nursing home antipsychotic use rate: how to check any home
Esta guía también está en español.
Key takeaways
- CMS publishes two antipsychotic measures for most certified nursing homes: the percentage of long-stay residents who received an antipsychotic medication, and the percentage of short-stay residents who newly received one. Both count in the quality measure star rating.
- On this site both rates are in the Quality measures section of each home's page, next to the state and U.S. averages. The U.S. long-stay average is 15.42% for July 2025 to June 2026; the short-stay average is 1.52% for July 2025 to June 2026.
- Neither rate is risk-adjusted. CMS leaves out residents with schizophrenia, Tourette's syndrome or Huntington's disease, and in its star rating it awards more points for a lower rate.
- Since January 2026, the long-stay measure also uses Medicare and Medicaid claims and Medicare Advantage encounter data, so long-stay rates from before and after that change are not directly comparable.
- Federal rules (42 CFR 483.45) limit "as needed" antipsychotic orders to 14 days, renewable only after the prescriber evaluates the resident. Since April 28, 2025, inspectors cite unnecessary psychotropic drug use under tag F605 instead of F758.
Short answer
CMS publishes two antipsychotic measures for most certified nursing homes: the percentage of long-stay residents who received an antipsychotic medication, and the percentage of short-stay residents who newly received one. On this site both are in the "Quality measures" section of each home's page, next to the state and U.S. averages. The U.S. long-stay average is 15.42% for July 2025 to June 2026.
To find a home, search by name, city or ZIP code, open its page and go to "Quality". To see several homes' star ratings side by side, compare homes; open each home's page for its antipsychotic rates.
What does the nursing home antipsychotic use rate measure?
The rate is the share of residents who got an antipsychotic drug during a set period, with long-stay and short-stay residents counted separately. For these measures, a resident is short-stay at 100 days or fewer in the home and long-stay at 101 days or more.
| Feature | Long-stay measure | Short-stay measure |
|---|---|---|
| What it counts | Residents who received an antipsychotic in the 3-month target period | Residents who were not on one at their first assessment but were later, in a 6-month target period |
| Data used | MDS assessments plus Medicare and Medicaid claims and Medicare Advantage records | MDS assessments only |
| Risk-adjusted? | No | No |
The MDS (Minimum Data Set) is the resident assessment the home sends to CMS. Both measures count in the quality measure star rating.
Which residents are left out?
CMS leaves out residents with schizophrenia, Tourette's syndrome or Huntington's disease from both measures. The rules differ:
- Long-stay. Since January 2026, the diagnosis must appear on the home's assessment and in Medicare or Medicaid claims from a one-year look-back period. Residents in hospice during the period, and residents without continuous Medicare (with drug coverage) or Medicaid enrollment, are also left out.
- Short-stay. The MDS diagnosis alone is used. Residents already on an antipsychotic at their first assessment, or whose use is unknown, are also left out.
Why did long-stay antipsychotic rates change in 2026?
CMS changed the long-stay measure with the January 2026 Care Compare refresh, adding Medicare and Medicaid claims and Medicare Advantage encounter data to the home's own assessments.
- What counts now. A resident is counted if the assessment shows antipsychotic use, or if a Medicare Part D or Medicaid pharmacy fill, or a Medicare or Medicaid claim for an antipsychotic given by a doctor or other practitioner, shows use while in the home.
- CMS's reasons. CMS said claims "will capture antipsychotic medication use that may be underreported on the MDS," including use outside its 7-day look-back window, and checking diagnoses against claims reduces exclusions from overreported schizophrenia.
- Effect on the national rate. CMS projected the national rate would rise from 14.64% to 16.98% "due to the new measure's inclusion of additional data."
- A correction. In April 2026, CMS fixed the calculation so all residents with a history of schizophrenia are excluded; some had not been in the January 2026 data.
Because the method changed, long-stay rates from before and after January 2026 are not directly comparable. The short-stay measure did not change.
How do I find a home's antipsychotic rate on this site?
Each home's page shows both antipsychotic rates in its "Quality measures" section.
- Find the home by name, city or ZIP code on the home page, or from your state's page, and tap "Quality" in its page menu.
- Under "Long-stay residents", find "Percentage of long-stay residents who received an antipsychotic medication".
- Under "Short-stay residents", find "Percentage of short-stay residents who newly received an antipsychotic medication". A star marks measures CMS uses in its quality rating. Each row shows this home, the state average and the U.S. average.
- Check the measure period in the note at the end of the section, listed "for most measures". It is currently July 2025 to June 2026.
- If there is no number, read the footnote text in its place (see below).
For how these measures fit into the overall rating, see how to read CMS star ratings. For a measure that CMS does risk-adjust, see checking a nursing home's bedsore rate.
How should I read the antipsychotic rate?
Read each rate as a percentage that CMS does not risk-adjust for residents' health. Instead, CMS leaves certain residents out, as listed above.
In the star rating, CMS awards more points for a lower rate on both measures. The long-stay measure is worth up to 150 points and the short-stay measure up to 100. A home with a short-stay rate of 0 gets the full 100 points.
What does it mean when the rate is blank?
A blank rate means CMS did not report one, and the home's page shows CMS's footnote text instead. CMS reports these measures only when they can be calculated for at least 20 residents' assessments, summed across four quarters.
| Text shown in place of the rate | What CMS says it means |
|---|---|
| Too few residents or stays to report (footnote 9) | The number of residents or stays is too small to report. CMS says to call the facility to discuss the measure. |
| Data missing or not submitted (footnote 10) | The data is missing or was not submitted. CMS says to call the facility to discuss the measure. |
| CMS could not validate the data (footnote 21) | "The accuracy of the data for this measure could not be validated by CMS." |
When a home has fewer than 20 residents' assessments for a measure, CMS may fill in the missing ones with the state average to compute the star rating. CMS does not publish those filled-in values, so they do not appear here.
What happens when CMS finds inaccurate schizophrenia coding?
CMS lowers the home's quality ratings. In 2023, CMS said wrong schizophrenia coding "can mask the facilities' true rate of antipsychotic medication use," and announced offsite audits of that coding. CMS's current rating guide says that for homes with coding inaccuracies found in these audits:
- The overall quality measure and long-stay quality measure ratings are lowered to one star for six months. CMS notes this drops the home's overall star rating by one star.
- The short-stay quality measure rating is suppressed for six months.
- The long-stay antipsychotic measure is suppressed for 12 months. In months 7 to 12, it gets the minimum points in the rating.
What is the antipsychotic use rate in each state?
The U.S. average is 15.42% for long-stay residents (July 2025 to June 2026) and 1.52% for short-stay residents (July 2025 to June 2026). Tap a state to see its homes.
| State | Long-stay % | Short-stay % |
|---|---|---|
| Alabama | 21.32 | 1.93 |
| Alaska | 18.92 | 0.62 |
| Arizona | 10.62 | 1.13 |
| Arkansas | 10.91 | 1.36 |
| California | 12.30 | 1.33 |
| Colorado | 19.88 | 1.58 |
| Connecticut | 17.74 | 1.39 |
| Delaware | 10.62 | 0.89 |
| District of Columbia | 8.56 | 1.17 |
| Florida | 8.68 | 1.41 |
| Georgia | 19.80 | 2.41 |
| Guam | – | 0.00 |
| Hawaii | 12.44 | 1.51 |
| Idaho | 20.33 | 1.70 |
| Illinois | 21.68 | 2.21 |
| Indiana | 13.73 | 1.13 |
| Iowa | 19.79 | 2.11 |
| Kansas | 17.70 | 1.64 |
| Kentucky | 16.20 | 1.62 |
| Louisiana | 22.76 | 3.11 |
| Maine | 19.50 | 1.47 |
| Maryland | 14.15 | 1.06 |
| Massachusetts | 21.46 | 1.37 |
| Michigan | 14.71 | 1.06 |
| Minnesota | 17.16 | 1.87 |
| Mississippi | 21.83 | 2.42 |
| Missouri | 23.54 | 2.10 |
| Montana | 20.75 | 1.22 |
| Nebraska | 20.70 | 2.10 |
| Nevada | 17.10 | 1.67 |
| New Hampshire | 17.86 | 1.19 |
| New Jersey | 12.86 | 1.12 |
| New Mexico | 14.50 | 1.23 |
| New York | 13.70 | 1.12 |
| North Carolina | 13.94 | 1.43 |
| North Dakota | 22.78 | 1.66 |
| Ohio | 8.48 | 1.20 |
| Oklahoma | 17.83 | 1.77 |
| Oregon | 14.28 | 1.40 |
| Pennsylvania | 17.63 | 1.37 |
| Puerto Rico | – | 0.45 |
| Rhode Island | 22.53 | 2.00 |
| South Carolina | 15.43 | 1.45 |
| South Dakota | 24.84 | 2.18 |
| Tennessee | 16.97 | 1.71 |
| Texas | 9.80 | 1.45 |
| Utah | 13.81 | 1.07 |
| Vermont | 19.96 | 1.40 |
| Virginia | 14.19 | 1.32 |
| Washington | 15.04 | 1.27 |
| West Virginia | 12.93 | 1.04 |
| Wisconsin | 15.86 | 1.16 |
| Wyoming | 21.44 | 1.62 |
| United States | 15.42 | 1.52 |
Averages come from CMS's State and US Averages file. For other state figures, see nursing home ratings and staffing by state and the site's data reports.
What federal rules apply to antipsychotics in nursing homes?
Federal pharmacy rules (42 CFR 483.45) list antipsychotics as one kind of psychotropic drug. Each resident's drug regimen must be free from unnecessary drugs. Based on a comprehensive assessment, the home must ensure that:
- A resident who has not used psychotropic drugs is not given them unless needed to treat a specific condition that is diagnosed and documented in the clinical record.
- A resident who uses them gets gradual dose reductions and behavioral interventions, unless clinically contraindicated, in an effort to stop the drugs.
- An "as needed" (PRN) order for a psychotropic drug is limited to 14 days. For psychotropic drugs other than antipsychotics, the prescriber can extend it by documenting the reason and how long.
- A PRN order for an antipsychotic is limited to 14 days and cannot be renewed unless the prescriber evaluates the resident. CMS guidance says this means directly examining the resident; a staff report to the prescriber is not an evaluation.
Residents have the right to be free from chemical restraints: drugs used for discipline or staff convenience that are not required to treat medical symptoms. CMS guidance says that before a psychotropic drug is started or increased, the resident or representative must be told its benefits, risks and alternatives, including any black box warnings for antipsychotics, and may accept or decline.
Inspection tags. Since April 28, 2025, inspectors cite unnecessary use of psychotropic drugs under tag F605 (chemical restraints). These requirements used to be under F758, so older inspection records may show F758. On this site, citations are listed in CMS's words, not tag numbers. For what the severity letters mean, see inspection severity letters A to L.
Since 2012, CMS's National Partnership to Improve Dementia Care in Nursing Homes has aimed at person-centered care and reducing unnecessary antipsychotic use. See also memory care vs. nursing home.
What can I ask a nursing home about antipsychotic use?
You can ask how the home follows the rules above: how it tells residents about a drug's benefits, risks and alternatives before it is started or increased, how it plans gradual dose reductions, and how it tracks the 14-day limit on "as needed" orders. If the home's page shows footnote text instead of a rate, you can ask what the home's own data shows. See also the questions to ask on a nursing home tour and nursing home residents' rights.
Who can I contact about an antipsychotic concern?
Federal rules name offices outside the home that residents can contact, including these two. Residents may file a complaint with the State Survey Agency about any suspected violation of state or federal nursing home rules. Representatives of the State Long-Term Care Ombudsman program identify, investigate and resolve complaints made by or for residents. Homes must post contact information for these offices, and the state pages on this site list them. For the steps, see how to file a complaint about a nursing home.